Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have received an average rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $105.30.

Several equities analysts have commented on IRON shares. Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday. Stifel Nicolaus decreased their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Finally, Morgan Stanley upped their price objective on shares of Disc Medicine from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, May 14th.

Insider Activity

In related news, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total value of $433,234.68. Following the transaction, the chief financial officer directly owned 64,333 shares in the company, valued at approximately $4,454,416.92. This represents a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Jacob Savage sold 5,731 shares of the company’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total transaction of $380,423.78. Following the completion of the transaction, the insider owned 79,480 shares in the company, valued at $5,275,882.40. This trade represents a 6.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,388 shares of company stock worth $841,258 over the last 90 days. 3.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Disc Medicine

Institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. grew its stake in shares of Disc Medicine by 3,329.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares in the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Disc Medicine in the third quarter valued at about $12,038,000. Hudson Bay Capital Management LP acquired a new position in shares of Disc Medicine in the third quarter valued at about $6,752,000. Vanguard Group Inc. grew its stake in shares of Disc Medicine by 3.7% in the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock valued at $95,688,000 after acquiring an additional 51,323 shares in the last quarter. Finally, First Light Asset Management LLC acquired a new position in shares of Disc Medicine in the third quarter valued at about $15,277,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Price Performance

NASDAQ:IRON opened at $67.99 on Friday. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The company has a market cap of $2.59 billion, a P/E ratio of -10.27 and a beta of 0.93. The firm’s fifty day moving average price is $68.16 and its two-hundred day moving average price is $72.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Equities analysts expect that Disc Medicine will post -6.74 earnings per share for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.